Citadel Advisors’s Intercure INCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-900
Closed -$1.26K 13730
2025
Q1
$1.26K Buy
900
+400
+80% +$646 ﹤0.01% 14152
2024
Q4
$800 Buy
500
+400
+400% +$629 ﹤0.01% 14267
2024
Q3
$201 Sell
100
-100
-50% -$210 ﹤0.01% 14077
2024
Q2
$402 Sell
200
-100
-33% -$272 ﹤0.01% 14003
2024
Q1
$813 Sell
300
-200
-40% -$340 ﹤0.01% 14242
2023
Q4
$640 Sell
500
-1,600
-76% -$1.95K ﹤0.01% 13978
2023
Q3
$3.32K Sell
2,100
-1,800
-46% -$2.87K ﹤0.01% 13601
2023
Q2
$6.63K Buy
3,900
+900
+30% +$1.97K ﹤0.01% 13414
2023
Q1
$6.12K Buy
+3,000
New +$9.02K ﹤0.01% 13828

Other funds holding INCR

Citadel Advisors's INCR Position: Q1 2026 in Review

Citadel Advisors increased its Intercure (INCR) stake by 102% in Q1 2026, buying an estimated $59K and bringing the position to 133,919 shares worth $101K. The position accounts for ﹤0.01% of the portfolio, ranked #12020.

Citadel Advisors first reported a position in INCR in Q3 2021 and has held it in 19 quarters since. The position peaked at $206K in Q4 2021. 15 funds tracked by Wall St. Rank hold INCR as of Q1 2026.

  • Citadel Advisors held 133,919 shares of Intercure worth $101K as of Q1 2026.
  • Citadel Advisors bought 67,666 Intercure shares in Q1 2026, an estimated $59K.
  • Intercure made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12020 holding.
  • Citadel Advisors first reported a position in Intercure in Q3 2021 and has held it in 19 quarters since.
  • Citadel Advisors's Intercure position peaked at $206K in Q4 2021.
  • 15 funds tracked by Wall St. Rank held Intercure as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.